Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083460 · ClinicalTrials.gov registry record · Phase 1
Study of Combination PS-341 and Thalidomide in Multiple Myeloma
A Phase 1 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 1
- Development phase
- 86
- Enrollment target
NCT00083460: Completed Phase 1 study, sponsored by University of Arkansas.
NCT00083460 is a Phase 1 study that has completed, run by University of Arkansas. The registered enrollment target is 86 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00083460, a Phase 1 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 86 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the toxicity of PS-341 combined with one of four doses of thalidomide in patients with refractory multiple myeloma, and to find the most appropriate doses of PS-341 and thalidomide in the combination.
Interventions
- DRUG Dexamethasone
- DRUG Thalidomide
- DRUG PS-341
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2001-12 |
| Est. Completion | 2007-11 |
| Phase | Phase 1 |
What the finished NCT00083460 record still lists
NCT00083460 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% higher).
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT00083460 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00083460 about?
NCT00083460 is a clinical study titled "Study of Combination PS-341 and Thalidomide in Multiple Myeloma". The purpose of this study is to assess the toxicity of PS-341 combined with one of four doses of thalidomide in patients with refractory multiple myeloma, and to find the most appropriate doses of PS-341 and thalidomide in the combination.
What is the current status of trial NCT00083460?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2001-12. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00083460?
The interventions under investigation include: Dexamethasone (DRUG), Thalidomide (DRUG), PS-341 (DRUG).
Who is sponsoring clinical trial NCT00083460?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00083460's enrollment target sits among peer trials
86 652nd of 2000 higher than 1,345 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia